Abstract
Background
Previous studies suggest low rates of hepatocellular carcinoma (HCC) screening in clinical practice. There is little information on the provider- and healthcare-facility-related factors that explain the use of HCC screening.
Aims
We used data from the 2007 Survey to Assess Hepatitis C Care in Veterans Health Administration that collected information regarding the care of patients with hepatitis C virus (HCV) from 138 of 140 Veterans Administration healthcare facilities nationwide.
Methods
All providers caring for veterans with HCV were invited to respond. In addition, each facility was asked to identify a lead HCV clinician to respond to facility-specific questions. Our outcome was a response concordant with HCC screening guidelines [HCC screening in patients with cirrhosis or in patients with chronic hepatitis B virus (HBV), and screening every 6 or 12 months].
Results
A total of 268 providers responded (98 % facility participation rate). Of these, 190 respondents (70.9 %) reported recommending HCC screening with guideline-concordant risk groups and frequency. Providers reporting guideline-concordant HCC screening practices were significantly more likely to have expertise in liver disease (MD, gastroenterologists or hepatologists), routinely screen for varices, prescribe HCV treatment, and refer or manage patients with liver transplant. The availability of HCC-specific treatments on site was the main facility factor associated with guideline-concordant HCC screening.
Conclusions
Self-reported rates of guideline-concordant HCC screening are considerably higher than those seen in routine VA practice. Provider expertise in liver disease and the perceived availability of HCC treatment including transplantation in the local facility are important factors driving self-reported HCC screening practices.
Similar content being viewed by others
References
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022.
Singal AG, Yopp A, Skinner S, et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med. 2012;27(7):861–867.
Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236.
Chalasani N, Said A, Ness R, et al. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol. 1999;94(8):2224–2229.
Van Kleek EJ, Schwartz JM, Rayhill SC, et al. Liver transplantation for hepatocellular carcinoma: a survey of practices. J Clin Gastroenterol. 2006;40(7):643–647.
HCV Infected Veterans in VHA Care in 2003 through 2007, for the Nation, by VISN and by Station. 2007.
Backus LI, Gavrilov S, Loomis TP, et al. Clinical case registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc. 2009;16(6):775–783.
Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–714.
Davila JA, Henderson L, Kramer JR, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011;154(2):85–93.
Davila JA, Weston A, Smalley W, et al. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2007;41(8):777–782.
Screening for Hepatocellular Carcinoma in HCV Infected Veterans with Cirrhosis in VHA Care in 2007 for the Nation, by VISN and by Station. 2007.
Wong CR, Garcia RT, Trinh HN, et al. Adherence to screening for hepatocellular carcinoma among patients with cirrhosis or chronic hepatitis B in a community setting. Dig Dis Sci. 2009;54(12):2712–2721.
El-Serag HB, Kramer JR, Chen GJ, et al. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011;60(7):992–997.
Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140(4):1182–1188.
Screening for Hepatocellular Carcinoma in HCV Viremic Veterans with Cirrhosis in VHA Care in 2011 for the Nation, by VISN and by Station. 2011.
Acknowledgments
This work is funded in part by NIH grant R01 CA125487 and in part by the Houston VA HSR&D Center of Excellence (HFP90-020).
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Appendices
Appendix 1: The Two Survey Questions from the Survey to Assess Hepatitis C Care in Veterans Health Administration That Were Used in This Study to Define the Two Outcomes of Interest
Which patients do you recommend for hepatocellular carcinoma (HCC) screening at your facility/(check all that apply) |
All patients with chronic hepatitis C infection |
Patients with chronic HBV infection |
Patients with cirrhosis |
Other patient groups (please specify) |
Patients with high risk for hepatocellular carcinoma (HCC) are screened every |
3 months |
6 months |
12 months |
Don’t screen |
Other (please specify) |
Appendix 2: The Questions Used in the Current Analysis
Rights and permissions
About this article
Cite this article
El-Serag, H.B., Alsarraj, A., Richardson, P. et al. Hepatocellular Carcinoma Screening Practices in the Department of Veterans Affairs: Findings from a National Facility Survey. Dig Dis Sci 58, 3117–3126 (2013). https://doi.org/10.1007/s10620-013-2794-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-013-2794-7